Curtis Oltmans serves as the Chief Legal Officer at Fulcrum Therapeutics Inc., a biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. In his role, Oltmans is responsible for overseeing all legal matters at the company, including corporate governance, intellectual property, and compliance. His strategic guidance has been instrumental in navigating the complex regulatory landscape of the biopharmaceutical industry and ensuring that Fulcrum remains at the forefront of innovation in rare disease treatments. Prior to joining Fulcrum Therapeutics, Oltmans had an extensive career in the legal field, with a particular focus on the life sciences sector. He previously served as the Chief Legal Officer at another biopharmaceutical company, where he played a key role in several successful drug launches and partnerships. Oltmans' expertise in intellectual property law has been crucial in securing and defending the company's patents, enabling Fulcrum to maintain a competitive edge in the market. His background also includes experience at top-tier law firms, where he advised clients on a wide range of legal issues, from mergers and acquisitions to licensing agreements. Oltmans' achievements extend beyond his professional accomplishments. He is recognized as a thought leader in the biopharmaceutical industry, often speaking at conferences and contributing to industry publications. His commitment to advancing the field of rare disease research is evident in his work at Fulcrum, where he has helped foster a culture of innovation and collaboration. Under his leadership, the company's legal team has been able to effectively support Fulcrum's mission to develop transformative therapies for patients in need.